CD47 and myeloid neoplasm: Upregulation of immune inhibitory checkpoints PD1, CTLA4, and CD47 has been consistently documented in myeloid neoplasms driving many prior clinical trials of antibodies aimed at blocking these proteins in patients with MDS and AML (38–42).